Table 1.
Patient characteristics of the study cohorts without left ventricular hypertrophy based on the 3 left ventricular mass index criteria.
| LVM/BSAASE cohort (n=337) | LVM/height2.7 cohort (n=325) | LVM/BSACT cohort (n=326) | |
|---|---|---|---|
| Demographics | |||
| Age, yrs | 52.7 ± 11.7 | 52.6 ± 11.8 | 52.7 ± 11.7 |
| Gender, male (%) | 206 (61.1%) | 196 (60.3%) | 198 (60.7%) |
| Race, black (%) | 30 (8.9%) | 27 (8.3%) | 29 (8.9%) |
| Body mass index, kg/m2 | 29.0 ± 5.8 | 28.6 ± 5.4 | 28.9 ± 5.8 |
| Body surface area, m2 | 1.99 ± 0.26 | 1.99 ± 0.26 | 1.99 ± 0.26 |
| Risk factors | |||
| Hypertension (%) | 127 (37.7%) | 117 (36.0%) | 121 (37.1%) |
| Diabetes (%) | 33 (9.8%) | 29 (8.9%) | 29 (8.9%) |
| Hyperlipidemia (%) | 120 (35.6%) | 114 (35.1%) | 115 (35.3%) |
| History of CAD (%) | 17 (5.0%) | 17 (5.2%) | 16 (4.9%) |
| Family history of CAD (%) | 83 (24.6%) | 80 (24.6%) | 80 (24.5%) |
| History of LV dysfunction (%) | 6 (1.8%) | 6 (1.9%) | 6 (1.9%) |
| Smokers (%) | 169 (50.2%) | 164 (50.5%) | 164 (50.3%) |
| Medications | |||
| Aspirin (%) | 103 (30.6%) | 99 (30.5%) | 98 (30.1%) |
| Statin (%) | 91 (27.0%) | 85 (26.2%) | 87 (26.7%) |
| Hypertensive Medication (%) | 125 (37.1%) | 115 (35.4%) | 119 (36.5%) |
| Beta-blocker (%) | 72 (21.4%) | 69 (21.2%) | 70 (21.5%) |
| ACE-I (%) | 45 (13.4%) | 39 (12.0%) | 40 (12.3%) |
| Presenting Characteristics | |||
| SBP, mmHg | 138.2 ± 21.9 | 137.8 ± 21.6 | 137.8 ± 21.6 |
| eGFR, ml/min/1.73 m2 | 84.6 ± 17.4 | 84.3 ± 17.6 | 84.3 ± 17.5 |
| HR during CT scan, beats/min | 65.4 ± 11.6 | 65.4 ± 11.7 | 65.4 ± 11.7 |
| CT Measurements | |||
| LV end-systolic volume, ml | 38.6 ± 18.1 | 38.6 ± 18.2 | 38.3 ± 18.1 |
| LV end-diastolic volume, ml | 117.1 ± 30.0 | 117.0 ± 30.0 | 116.5 ± 29.7 |
| LV ejection fraction, % | 67.9 ± 9.2 | 67.9 ± 9.2 | 68.0 ± 9.3 |
| LV inner diameter, mm | 47.5 ± 5.4 | 47.5 ± 5.4 | 47.5 ± 5.4 |
| RWT ratio | 0.36 ± 0.09 | 0.36 ± 0.09 | 0.36 ± 0.09 |
| Presence of any coronary plaque | 168 (49.9%) | 162 (49.9%) | 163 (50.0%) |
LVM denotes left ventricular mass; BSA, body surface area; ASE, American Society of Echocardiography; CT, computed tomography; CAD; coronary artery disease; LV, left ventricular; ACE-I, angiotensin converting enzyme inhibitor; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; HR, heart rate; and RWT, relative wall thickness.